Download Booklet - Diabetes in Asia Study Group

DEBATE
Are the new diabetes related treatments cost effective? NO
Dr. Shaukat M.Sadikot,
Many new types of medications have been introduced in recent times in the quest to optimize
glycemic control. an additional benefit attributed to many of these medications are their pleiotropic
effect which is thought to go beyond glucose control and help in ameliorating the complications
associated with diabetes especially the macrovascular complications. Many of these claims are
pushed by pharmaceutical companies and are to withstand rigorous and impartial scientific
scrutiny. at the same time these new medications have also been shown in follow up studies to
be associated with side effects which were not known or, if known, not widely publicized. but one
aspect which is often never considered in scientific academia is the significant high price of these
new medications which often put an unacceptable burden on the common person, especially
those who economically challenged. Moreover, do these new and costly medications really offer
a more optimal level of benefit, especially when compared to the older and relatively cheaper
diabetes treatment modalities?
Sir Michael Hirst
Abstract of Sir Michael Hirst’s presentation
Michael hirst will talk about what brought him into diabetes in the first place – the diagnosis of his
youngest child with type 1 diabetes at the age of four – and how, almost by accident, he became
a diabetes champion. he will describe how he used his experience of parliament and Government
to win improvements in diabetes care, and the critical role of advocacy in securing both greater
awareness of diabetes among health policymakers as well as service enhancements for people
with diabetes.
Michael will trace his long apprenticeship in diabetes, through Diabetes uK, the un resolution
campaign, to membership of the iDf board, and election as president-elect of iDf at the Montreal
Congress. he will outline the major challenges facing the international Diabetes federation as the
authentic voice of the 285 million people with diabetes, and the imperative of making world leaders
take the diabetes pandemic much more seriously. he will talk of some of his own ambitions for
the world’s largest health consumer organisation as he looks to his presidency after he succeeds
professor Jean Claude Mbanya at the end of 2012. Michael will be the last president to serve a full
triennium, so this means that he will be president at both the 2013 World congress in Melbourne
and at the 2015 Congresses.
32